Covid-19
Advertisement

New Anti-Aging Clinical Trial Charges $1 Million to Participate

The treatment will be administered in Columbia beyond the reach of the U.S. Food and Drug Administration.

What would you do to reverse the aging process? Everywhere we look it seems that anti-aging efforts are all the rage.

RELATED: 12 INNOVATIONS THAT COULD MAKE REVERSE AGING A REALITY

 A hefty participation price

Now, an American biotech company is launching a new anti-aging clinical trial and charging an exorbitant $1 million dollars to participate. This is in stark contrast to most clinical trials that are either free or offer compensation.

What is this trial that can charge such a high fee? According to a report by OneZero, it is a treatment that lengthens a person’s telomeres.

Libella Gene Therapeutics, a Kansas-based company, is saying that this process could help reverse aging by almost 20 years and even fight off age-related diseases such as Alzheimer's.

“I know what we’re trying to do sounds like science fiction, but I believe it’s a science reality,” Jeff Mathis, CEO of Libella Gene Therapeutics, told OneZero.

The firm's website boasts that the "future is here" and offers three gene therapies: one for Alzheimer's, one for the treatment of aging and one for limb ischemia. "Gene therapy offers the ability to permanently correct a disease at its most basic level, the genome, and could offer cures for many conditions that are currently considered incurable," said the firm's press release from January 2018.

What could go wrong?

Could this approach possibly work? Although no one can know for sure, the fact that the firm took its trials all the way to Colombia, beyond the reach of the U.S. Food and Drug Administration (FDA), should raise some eyebrows, experts told OneZero.

“Even though the company is based in the United States, they’ve managed to find a way to evade U.S. federal law by going to a jurisdiction where it’s easier to engage in this activity,” Leigh Turner, a bioethicist at the University of Minnesota, told OneZero.

“I think of this as a study where many things could go wrong,” added the expert. 

Advertisement

Stay on top of the latest engineering news

Just enter your email and we’ll take care of the rest:

By subscribing, you agree to our Terms of Use and Privacy Policy. You may unsubscribe at any time.

Advertisement